Johnson & Johnson (JNJ)
NYSE:JNJ
Want to see JNJ full AI Analyst Report?
JNJ Stock Chart & Stats
$234.54
-$4.08(-2.79%)
At close: 4:00 PM EST
$234.54
-$4.08(-2.79%)
Day’s Range― - ―
52-Week Range$146.12 - $251.71
Previous CloseN/A
Volume3.80M
Average Volume (3M)7.33M
Market Cap
$574.86B
Enterprise Value$592.57B
Total Cash (Recent Filing)$20.10B
Total Debt (Recent Filing)$47.93B
Price to Earnings (P/E)18.8
Beta0.08
Next Earnings
Jul 22, 2026EPS Estimate
2.85Next Dividend Ex-DateN/A
Dividend Yield2.5%
Share Statistics
EPS (TTM)2.70
Shares Outstanding2,408,613,300
10 Day Avg. Volume6,434,853
30 Day Avg. Volume7,328,201
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue6.29
Enterprise Value/Gross Profit9.27
Enterprise Value/Ebitda14.51
Forecast
1Y Price Target
$261.43Price Target Upside11.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)11.58
Revenue Forecast (FY)$100.76B
Bulls Say, Bears Say
Bulls Say
Guidance And Margin ImprovementModest guidance increases combined with favorable phasing and improving profit dynamics as launch investments are lapped suggest upside to earnings power.
New Product Launches Driving SalesStrong commercial momentum from recent launches such as Tremfya and Icotyde is outpacing expectations and supports potential upward revisions to sales forecasts.
Pipeline And Label ExpansionOngoing Phase 3 programs and head-to-head studies provide opportunities for label expansion of key assets, which could materially increase long-term revenue potential.
Bears Say
Competitive Efficacy ConcernsPerceptions that injectable IL-23 therapies deliver superior efficacy could limit Icotyde's market share and constrain peak sales potential.
Medical Device Segment HeadwindsMedical device operations are exposed to currency swings, geopolitical disruptions and supply chain pressures that may weigh on near-term performance and margins.
Pricing And Access Uncertainty For IcotydeLimited visibility on Icotyde's pricing and access strategy, along with unclear sampling plans, could slow prescription uptake and create near-term revenue uncertainty.
Johnson & Johnson News
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $146.12 and its highest was $251.71 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $574.86B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jul 22, 2026 which is in 95 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Apr 14, 2026. The company reported $2.7 earnings per share for the quarter, beating the consensus estimate of $2.677 by $0.023.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 2.5%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.85.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,408,613,300 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.7 in its last earnings report, beating expectations of $2.677. Following the earnings report the stock price went up 0.899%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in JNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$261.43 (11.46% Upside)
$261.43 (11.46% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 94%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $79.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 90%
Bearish news 10%
Bearish news 10%
Company Description
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
JNJ Company Deck
JNJ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive commercial and pipeline story: strong top-line operational growth, multiple high-growth products (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT, TREMFYA) and successful new launches (ICOTYDE, INLEXZO) with raised full‑year guidance and clear long‑term targets (line of sight to double‑digit growth by decade end). Offsetting these positives were significant short‑term headwinds—most notably a steep STELARA decline, GAAP EPS volatility driven by prior-year one‑time items, margin deleverage from heavier launch investments and a soft Q1 free cash flow run‑rate. Management emphasized confidence in recovery/acceleration through the year, substantial R&D and manufacturing investments, and multiple upcoming catalysts, leading to an overall constructive outlook despite near‑term profitability and comparability pressures.View all JNJ earnings summariesJNJ Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
$261.43
▲(11.46% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
18.59% Mutual Funds
0.26% Other Institutional Investors
57.73% Public Companies and Individual Investors